Ultrasound Probe Recall Review and Fleet Care (2026)

Start by identifying what the recall record describes

The FDA database creates records around corrections and removals and subsequently records classification and termination information. One underlying action can have several product recall numbers. The recalled item may be an accessory used with a transducer even when the product-code label says diagnostic ultrasonic transducer. The record's product description and action field therefore matter more to the response than the search label alone. ²

We selected ITX, HGL, JOP and OQQ in a 58,785-row recall export captured in the August 24, 2026 source snapshot. The result has 152 distinct recall numbers: 147 under ITX, four under HGL and one under JOP; OQQ contributes none in this export. These are records within a defined search, not a census of every ultrasound-related field action or every event affecting probes worldwide. ¹

FDA's classification page identifies ITX as diagnostic ultrasonic transducer under 21 CFR 892.1570. That explains the initial search choice. The item type still has to be established from the actual product description. A selected Exact Medical record, for example, identifies a kit and discusses the permitted use of transducer covers. Gel and needle-guide records create similar scope differences. ^{3 4}

This creates a useful operational split. A reusable transducer is usually controlled by model and serial number. A disposable cover or gel supply is often controlled by catalog number, lot and expiration date. A system software correction adds console identity and version. A service organization that stores only the probe's model name will struggle to determine which patients, departments or supplied products are potentially affected by the other record types.

The selected records also demonstrate why image quality is an incomplete intake screen. A gel lot can be microbiologically contaminated while the probe produces an apparently satisfactory image. A cover can have an inappropriate intended-use claim while fitting the transducer. A system can display an image while a safety-related function requires correction. These are different questions for different evidence owners.

Our recommendation is to keep three connected lists: reusable assets, consumable lots and open manufacturer actions. Link them through the relevant clinical workflow and supplier records. This is an information-management recommendation derived from the mixed cohort, rather than a new universal regulatory requirement. Its value is that a notice can be routed to the responsible team without first reconstructing the equipment pathway from memory.

A receiving team should therefore identify the actual article before deciding what to inspect. A sealed sterile cover, a reusable TEE transducer returned from repair and a nonsterile bottle of coupling gel have different acceptance criteria. A single generic field labeled “probe checked” would conceal those differences. The record should show which item was checked, against which instructions and with what result.

What the 152 records establish, and where the extract stops

The structured cause field is headed “FDA Determined Cause” on the public recall pages. In the selected extract, process control accounts for 49 records, device design for 27, other for 30 and no marketing application for 18. The remaining 28 span process design, software and several smaller categories. Process control and device design together account for 76 of 152 selected records, exactly one half. ¹

This distribution describes the recorded cause categories for a mixed set of products and actions. A cause labeled process control may concern refurbishment, manufacturing or another process depending on the record. It is not a diagnosis of the probe on a technician's bench. Nor does a label establish that normal handling, aging or cleaning caused a particular defect.

The earlier keyword classification was especially vulnerable to overinterpretation. It assigned each reason to the first matching theme. A reason containing both labeling and an imaging issue could be placed in labeling; a structural issue that affects ultrasound attenuation could enter the structural bucket. A small imaging-only bucket therefore says little about how often imaging performance matters. We have removed the claim that only two records concern the clinically important image-quality problem.

A more defensible use of the text is to identify explicit clusters and inspect their full notices. Thirty-four Philips records in 2025 contain one of two useful-life statements. Eighteen Exact Medical records contain the same marketing-authorization reason. Seventeen records explicitly mention Eco-Med. Those bounded text matches support targeted follow-up. They leave room for records with different wording or missing text. ¹

The limitations in the exported text are measurable. Twelve selected rows have an empty recall reason. Twenty-three reasons are exactly 300 characters long, and several end mid-sentence. A blank should remain unknown until checked; a shortened reason should trigger retrieval of the complete record. Classifying either as a low-consequence event would substitute a data-quality problem for a safety assessment.

A simple grouping exercise further shows the difference between rows and events. Grouping by normalized firm name, initiation date and exact exported reason reduces 152 rows to 64 groups. This is a reproducible grouping proxy, not a validated count of independent recalls: separate actions can share text, and one action can appear on different dates or under different names. The export lacks the event identifier needed for an authoritative event-level reconciliation. ¹

For a fleet manager, that means two records with similar titles should be investigated together but closed separately against the actual affected assets. The team needs the complete notice, product identifiers and documented response. A spreadsheet count can prioritize the investigation; it cannot replace the manufacturer's disposition instructions.

The Philips useful-life cases require two different responses

The largest 2025 cluster illustrates why a theme is insufficient to prescribe action. Twenty-one selected records state that ultrasound transducers were refurbished beyond their useful life. The corresponding FDA record for a 3D9-3v transducer describes a replacement program under a May 28, 2025 notice. It allows use while awaiting replacement subject to the notice and user-manual instructions, including inspection and electrical-safety testing, with removal from clinical use if the device fails inspection. ⁵

Another thirteen selected records concern clarification and labeling of useful life. The FDA record for C6-3 describes obtaining manufacturing certificates by serial number and retaining them with system documentation. It gives different expected lives for named transducer groups and directs users beyond the stated life to performance testing or Philips guidance. Those instructions differ from a blanket requirement to discard every older probe. ⁶

The first procurement question is therefore identity. Does the specific serial number appear within the correction, and which notice applies? A matching model family alone may be insufficient. Manufacturing date, refurbishment history and the notice's scope can determine the next step. The supplier should provide enough information for the responsible facility team to establish that relationship before accepting a replacement or repaired unit.

Useful life also differs from several dates commonly held in asset systems. Purchase date can follow manufacture by years. The date a second-hand probe enters the current hospital says little about its earlier service. A repair date identifies an intervention, not automatically the start of a new manufacturer-supported life. Preserve those dates as separate fields and use the manufacturer's stated basis for any calculation.

A practical asset record can contain model, serial number, manufacturing evidence where available, first known service date, known repairs, applicable useful-life instructions and outstanding actions. When a field is missing, assign an owner to obtain it or escalate the uncertainty. Inventing a manufacture date from a clearance date would create false confidence precisely where the notice requires product-level identification.

FDA's September 2025 warning letter to Royal Philips adds a related quality-system signal. It discusses the manufacturer's useful-life treatment in refurbishment and difficulties analyzing refurbishment history. This is a finding about the inspected operations described in that letter. It supports asking for traceable service history; it does not establish that every independently repaired probe is defective or that every older probe shares the same disposition. ⁷

For a service quotation, useful-life status should be resolved before promising an economic repair. A technically repairable cable fault may coexist with an open OEM replacement action. In that situation, the quotation should identify the action and let the owner coordinate the applicable remedy. Repair expenditure becomes meaningful only after the asset's permissible route back to service is understood.

For a distributor, the same evidence belongs in the sales handoff. A buyer should receive the specific model and serial identity, the known condition and repair history, and documentation of applicable actions. Describing an item as tested or refurbished answers only part of that request. The record should make clear what was checked and what remains for the receiving facility to verify.

Covers and gel turn probe care into a supply-chain task

The eighteen Exact Medical records change the meaning of the cohort. Their shared reason concerns a cover's lack of clearance for use in a natural or surgical opening. The reviewed FDA notice limits the existing cover use to external intact skin and describes the correction sent to consignees. That is a product intended-use issue, rather than evidence that eighteen transducer models developed a hardware defect. ⁴

A distributor checking only dimensions could miss this distinction. Fit, sterility status and permitted clinical application are separate properties. The approved purchasing specification should identify each, and the receiving record should link the supplied catalog number to that specification. A cover that fits an endocavity probe still requires evidence that its labeled use is suitable for the intended application.

The gel-related records add a different traceability requirement. Seventeen reasons in the selected extract explicitly mention Eco-Med, spread across distributors and product descriptions. CDC's investigation of the 2021 outbreak links infections to contaminated nonsterile, multiuse ultrasound gel. It reports contaminated tested lots and describes the escalation of the recall. This gives an independent clinical-public-health lane beyond the recall-number count. ⁸

The operational lesson is lot identity across purchasing and use. Store brand, manufacturer where identified, catalog number, lot, expiration date and receiving or distribution location. If a supplier distributes the same manufactured gel under several labels, the lookup needs those relationships. Searching only the label most familiar to the department may miss the underlying manufacturer named in a safety communication.

CDC's later investigation of Paraburkholderia associated with nonsterile ultrasound gel reinforces the application-specific issue. Its report covers detections across the United States, Canada and Israel during 2023 through 2025 and reiterates the use of sterile gel for percutaneous procedures. These findings support reviewing gel selection within the relevant procedure workflow, rather than treating all coupling products as interchangeable. ⁹

Neither a clear-looking bottle nor intact packaging establishes microbiological safety. Visual inspection can identify damage, leakage, an expired date or a mismatched label. A contamination notice can require action even when none of those conditions is visible. Staff should follow the applicable recall instructions and facility infection-prevention process, including identification and removal of affected stock where instructed.

The same distinction applies to sterile packaging. A visible seal defect is a reason to hold the item under the facility's procedure. An intact seal is only one component of acceptance; the label, lot, shelf life, storage conditions and any applicable action remain relevant. Opening a sterile package solely to inspect the contents would itself disrupt the sterile barrier, so receiving checks must preserve it.

Needle guides create another interface. The selected records include guides and brackets with cover-puncture or assembly issues. The item can affect the barrier around an otherwise functional transducer. A procurement record should therefore preserve the specific guide, cover and transducer combination established by the relevant instructions. Substituting a nearby catalog number because the parts appear to fit can undermine the evidence on which the combination was accepted.

For a service company, the right handoff may be to procurement or infection prevention rather than to a repair bench. A gel lot correction calls for stock and distribution controls. A cover intended-use correction calls for specification and use review. A reusable transducer fault calls for qualified technical assessment. Recording that routing decision prevents a technically competent repair team from being assigned a problem it has no authority or equipment to resolve.

Reprocessing and technical acceptance answer different questions

Reprocessing should follow the exact device instructions, the intended use and the facility's applicable infection-prevention policy. FDA's guidance addresses validated reprocessing instructions and labeling for reusable devices. It is a framework for the manufacturer's evidence and instructions, not a universal recipe for every transducer, connector, cable or accessory. ¹⁰

CDC recommends cleaning and high-level disinfection for semicritical devices such as vaginal and rectal probes even when covers are used. The cover reduces contamination but can fail. For equipment entering normally sterile tissue, the applicable sterilization requirements and device-specific instructions require separate assessment. A care protocol must distinguish these uses rather than applying “HLD for every probe” as an undifferentiated rule. ¹¹

AIUM's 2025 statement covers preparation of external- and internal-use transducers, equipment and coupling gel. Its breadth is relevant to the mixed recall cohort: the workflow includes surfaces, barriers and gel as well as the transducer. Facilities should reconcile professional guidance with the actual product labeling and applicable local requirements through their infection-prevention leads. ¹²

Philips' care resources likewise direct users to the instructions and compatible cleaning or disinfection products for the exact equipment. Immersion limits, chemical compatibility and handling requirements vary. A repair provider should request the facility's recorded process when investigating damage, while avoiding an unsupported assertion that a particular chemical caused the fault. The history is an investigation input. ¹³

Technical acceptance must then establish the relevant performance and safety evidence. An image on a compatible console can help assess imaging function. It leaves other questions for separate testing, including electrical safety or specific probe functions when required by the manufacturer and service procedure. A passed check should identify the method, equipment, acceptance criterion and tested asset.

The temperature-programming case makes this separation concrete. The reviewed Philips TEE recall describes a programming issue affecting the system's ability to measure tip temperature and gives a specific verification procedure for affected combinations. A generic statement that the latest firmware is installed would not establish that this prescribed check was completed. The technician must use the complete notice and applicable service instructions. ¹⁴

A safe handoff therefore records the exact system and transducer combination, applicable software state, specified checks and disposition. If the notice names particular versions or serial ranges, retain them with the work order. Avoid updating equipment merely because a newer version exists: version changes should follow the authorized service route and compatibility requirements for that model.

A returned asset also needs a defined contamination status before handling or shipment. The facility and service provider should agree on the required preparation, documentation and packaging, using applicable instructions and transport requirements. A label that says “cleaned” is insufficient if the receiving party cannot tell what process was used or whether the device may safely enter its workflow.

Rongtao's probe high-level-disinfection report addresses the reprocessing layer in more detail. This recall review adds a complementary decision: whether the exact asset, accessory or consumable has an unresolved field action that changes its acceptance. Both checks belong in the record, with named owners and separate evidence. ¹⁵

The clearance series is a search boundary, not a fleet-age curve

The second dataset contains 175,559 510(k) records in its frozen export. Selecting the same four primary product codes gives 518 rows. Of these, 507 are labeled substantially equivalent, ten substantially equivalent for some indications and one unknown. A clearance-oriented analysis should therefore distinguish the 517 affirmative decision records from the complete 518-row selection. ^{1 16}

The distinction changes the 2000s count from 94 selected rows to 93 affirmative decisions. The corresponding affirmative-decision counts are four for the 1970s, 150 for the 1980s, 194 for the 1990s, 93 for the 2000s, 53 for the 2010s and 23 for the incomplete 2020s window in this extract. A table is more appropriate than a trend headline that treats those periods as equivalent exposure. ¹

Several variables are missing from that series: number of models associated with each submission, secondary product codes, units manufactured, units sold, retirement dates and installed assets. A 510(k) can describe a system and several transducers; counting one primary code does not reconstruct all compatible probe introductions. FDA's ultrasound-system summary for K150148, for example, describes support for additional transducers within a system submission. ¹⁷

Clearance date is also a regulatory milestone rather than a manufacture date. An older clearance can support later-manufactured devices within its scope. A hospital can purchase a new unit from a long-running family or acquire a used unit with a short local service history. Those situations require different inventory evidence even though a search might point to the same original decision.

The support-planning implication is specific. Use the regulatory record to confirm the relevant device identity and intended-use context; use the supplier's current documentation and the facility's actual inventory to assess support and age. Rongtao's model-record change audit likewise treats register changes as support-planning signals with defined limitations. A withdrawal from commercial distribution requires interpretation alongside manufacturer support, available parts and the particular asset. ¹⁸

For purchasing, request the evidence needed to answer the missing variables. A buyer comparing two replacement offers should seek exact model and serial identity, known manufacture or service history, applicable compatibility, correction status and available acceptance evidence. The clearance record can support the regulatory part of that investigation. It leaves the condition and history of the offered unit to be established separately.

The same logic protects spare-parts planning. A decline in selected primary-code decisions provides no reliable demand forecast for a particular replacement cable or exchange probe. Stocking should use the installed fleet, observed service requests, lead times, known support changes and compatibility evidence. The public record adds alerts and context to those inputs; their missing denominators must come from the fleet and service records.

Route each finding to a documented disposition

The reviewed cases support a compact response map. Its purpose is to assign the right next action, not to authorize work on an affected product. The controlling instruction remains the complete applicable notice, device labeling and the facility's qualified decision process. FDA's device-recall information distinguishes correction from removal, which helps explain why an action can involve instructions, repair or replacement rather than a single universal response. ¹⁹

When a new notice arrives, first identify the affected item. Compare model, catalog number, serial or lot scope, relevant dates and software conditions. Preserve both the original notice and the record of the comparison. If the local asset identifier is incomplete, hold the decision open and assign the missing-information task; a guessed match can be as disruptive as a missed one.

Next, establish the controlling action. Some notices direct users to stop use or remove stock. Others prescribe an inspection, label update, software correction, replacement process or communication to users. The two Philips useful-life cases illustrate why the team should capture the action text and source revision, rather than substituting a generalized rule for an entire brand.

The responsible owner then records the physical disposition. An asset awaiting review needs a location and status that prevent accidental release. A consumable lot may need stock reconciliation across rooms or distribution customers. A product awaiting an OEM replacement may require the notice-specific interim conditions to remain with it. The process should show what is available for use, what is held and who can change that status.

Completion requires evidence appropriate to the action. A return shipment may need a receipt; a replacement may need the new serial identity; a prescribed check may need a dated result and the responsible person's signoff. A communication action may need confirmation that the relevant users received the instructions. The evidence should explain how the affected population was reconciled, including items already transferred or disposed of.

Finally, reconcile the closeout with the asset or lot record. A completed work order that leaves an old open-action flag can cause unnecessary holds; a closed flag without the supporting work can conceal an unresolved risk. The closeout should point to the evidence and identify any ongoing restrictions. This is where an equipment register becomes operationally useful rather than simply comprehensive.

Consider an illustrative external-probe repair intake. The customer reports intermittent image dropout and supplies a model name but no serial photograph. The repair team can discuss a diagnostic route, but an unconditional repair-and-return promise would be premature. First obtain the identity, intended use, host system, relevant instructions and known action status. If an applicable OEM action changes the disposition, address it alongside the technical assessment.

Now consider an illustrative gel-lot alert. The probe has passed its technical tests, yet purchasing records show a gel manufacturer named in a safety communication. Repeating the probe's image test would leave the relevant question unanswered. Procurement and infection prevention need the lot and distribution history, the notice's scope and documented stock action. The repair record can remain valid while the consumable workflow requires a separate intervention.

These examples use no assumed success rates or fixed turnaround. Their point is sequencing: identify the item, establish the governing action, assign the correct owner, document the outcome and reconcile the record. The recall evidence earns this sequence because the selected cohort spans several different items and disposition types.

Decide repair versus replacement after resolving the action

A repair comparison should begin with admissible options. If an applicable notice directs a particular remedy, incorporate that remedy before comparing prices. If the unit fails a required safety check, follow the prescribed removal or escalation route. A low repair quotation has little decision value until the owner knows the conditions under which the asset could return to service.

For the remaining options, compare the full service episode. Relevant components may include assessment, repair, required testing, transport, a loaner or temporary replacement, expected downtime and the documentation needed for acceptance. Use the supplier's actual quotation and the facility's own scheduling costs. The recall export contains no repair-cost distribution from which to derive a universal repair-versus-replacement percentage.

A replacement offer needs equivalent scrutiny. Check identity, compatibility, condition, correction history and supplied evidence. An exchange probe may solve the immediate downtime problem while introducing uncertainty about the replacement's earlier service. The acceptance record should resolve that uncertainty to the degree required for the intended use, rather than treating “replacement” as a complete description of quality.

FDA's remanufacturing guidance distinguishes activities that restore a device to its original specifications from changes that significantly alter performance, safety specifications or intended use. The assessment depends on the activities performed. A work order should therefore describe the repair and any component or process changes accurately; the label “servicing” by itself does not settle the regulatory characterization. ²⁰

This boundary is relevant to a proposed substitution. A supplier should explain the basis for compatibility and verification when a component differs from the original configuration. The customer should understand what was changed and what evidence supports the returned state. The public recall cohort includes concerns around inadequately verified components in serviced equipment, which makes that evidence a concrete procurement issue rather than an abstract preference. ¹

Rongtao provides independent ultrasound service and probe solutions. Its published process describes verification and real-machine testing with supporting evidence. A quotation should state the checks applicable to the exact item; such testing supports the supplied service scope and is separate from any OEM correction or facility reprocessing obligation. OEM names identify service coverage or compatibility, without implying authorization or endorsement. ²¹

The service handoff should also define what the receiving facility must verify. A proposed acceptance pack can identify the returned serial number, the reported symptom, the work performed, the test configuration, the dated results and any limitations or unresolved items. If a loaner was supplied, reconcile its identity and return separately from the repaired asset. This avoids closing the wrong equipment record when several visually similar probes move through the same department.

Agree on how discrepancies are handled before dispatch. For example, the returned item may have a different connector revision from the one photographed at intake, or the supplied test report may identify a host system that differs from the facility's intended configuration. The receiving team should have a named contact and a way to keep acceptance pending while the discrepancy is resolved. Record the explanation and supporting evidence with the final acceptance decision. These are proposed purchasing and handoff controls, to be adapted to the exact device, applicable instructions and facility procedures; they establish no substitute test method or automatic authorization to return a device to clinical use.

An actionable enquiry to probe repair or Rongtao's contact team should include the manufacturer, model, serial-label photographs, compatible system, observed symptom, known damage and service history, applicable notice, quantity and destination. Share a documented contamination status through the agreed service process. These details allow the provider to scope an assessment and identify missing evidence before transport or commitment.

Set monitoring around incoming notices and the real fleet

Scheduled database searches are a backstop. They should complement manufacturer and distributor communications, facility safety alerts and the relevant national authority's notices. A serious incoming action may require prompt handling; waiting for the next quarterly spreadsheet review would defeat the purpose of the alert. The 2021 gel investigation shows how an action can expand as additional evidence emerges. ⁸

Choose the search cadence through the facility's risk and quality process. The 152-row export supplies no validated universal interval, and it gives no basis for claiming that all facilities can complete monitoring in fifteen minutes. A small outpatient fleet and a distributor serving many customers have different reconciliation workloads. Measure the actual effort before assigning responsibility and capacity.

Search beyond the four cohort codes when the fleet warrants it. The actual system, specialty transducer, needle guide, cover, gel and reprocessing equipment may appear under additional codes or descriptions. Build queries from known manufacturers, model aliases and supply records as well as product codes. The cohort's own mixture is evidence that a code-only search should be supplemented by product-level matching.

A useful monitoring log records the date, source checked, query scope, notices found, affected local identifiers, responsible owner and current disposition. An empty result should say what was searched and when. It establishes the scope of that check, while new information or an incoming supplier notice can still trigger review. Preserve superseded notices when they explain earlier action, and make the current instruction easy for users to find.

The metric worth reviewing is whether affected products can be identified and reconciled. Counting searches completed says little if lot numbers are unavailable or transferred probes disappear from the asset list. A periodic exercise can select one real, applicable historical notice and reconstruct the response from records: affected inventory, decision, completed action and remaining uncertainty. Resolve the weakest link before adding more fields to the register.

Methods and limitations

The computation uses read-only, checksum-verified FDA recall and 510(k) exports selected through the shared data catalog. The raw snapshot date is August 24, 2026; data content and individual initiation dates have their own ranges. The selected recall initiation dates run from May 7, 2004 through November 17, 2025. The snapshot date should not be mistaken for an event date or proof of complete contemporary surveillance. ¹

Selection is an exact match on the exported primary product-code field for ITX, HGL, JOP or OQQ. Recall numbers are distinct within the 152 selected rows. Structured cause labels are retained without recoding. Explicit text matches identify the Philips, Exact Medical and Eco-Med examples; full public notices supply the action interpretation. Empty and apparently shortened reasons remain documented data limitations.

The 64 grouping proxies use normalized firm name, initiation date and exported reason. They are a sensitivity check on row multiplicity, not independent event counts. The annual sequence uses initiation year, which differs from posting date and the year printed in a recall number. The 510(k) table separates all selected rows from affirmative decisions and labels the current decade as incomplete.

This analysis has no installed-unit, patient-exposure, scan-volume or repair-work-order denominator. It cannot estimate incidence, compare brand safety or rank the frequency of ordinary probe faults. It also excludes many ultrasound-related codes and worldwide actions. The public supplement provides the aggregate results and selected recall identifiers so readers can inspect the selection and retrieve the relevant current records. ¹

The decision map is Rongtao's operational synthesis of the record review, public-health evidence and manufacturer/professional instructions. It is intended for qualified procurement and service teams. Device-specific actions, current instructions and the facility's applicable clinical and quality requirements determine the final disposition of any individual item.

Frequently asked questions

Does a terminated recall make a second-hand unit acceptable?

Termination is a status of the recall action. Acceptance of a specific second-hand unit still requires identity, applicable correction evidence, condition and the checks required for its intended use. Retrieve the relevant record and supporting documentation rather than using the status field as a substitute for the asset's history. ²

Should every probe beyond its stated useful life be discarded?

Follow the exact manufacturer's instruction and applicable notice. The reviewed Philips records include both a replacement action with stated interim conditions and a useful-life clarification that directs testing or manufacturer guidance. Their different instructions are the reason to match the serial identity and action before deciding. ^{5 6}

Can an image-quality test close a gel or cover alert?

An imaging test addresses a different question. A gel alert requires identification and disposition of the affected supply; a cover alert can involve its intended use, barrier or lot. Keep those actions linked to the workflow while retaining separate evidence of probe performance and reprocessing. ^{4 8}